par Lefranc, Florence ;Mathieu, Véronique ;Kiss, Robert
Référence Oncotarget, 2, 12, page (892-893)
Publication Publié, 2011-12
Article révisé par les pairs
Résumé : Altogether, these findings clearly point to the fact that decreasing galectin-1 expression ( e.g., using monoclonal antibodies or siRNAs ) in melanomas and gliomas may weaken the defenses of these two types of cancers against radiotherapy, chemotherapy and immunotherapy/vaccine therapy; may reinforce antiangiogenic therapies; and may weaken both the invasive capacities of these cancers towards neighboring tissues (such as the brain parenchyma for gliomas) and (in the case of melanomas) their metastatic rates.